ViaScint may help cardiac bypass patient selection
This article was originally published in Clinica
Executive Summary
First results from Phase III trials with Medco Research's (US) imaging agent, ViaScint, suggest it can predict which patients will have improved cardiac function following revascularisation. The multicentre trials involving 200 patients in the US and Canada "are the first large multicentre prospective studies to evaluate residual myocardial viability in a population known for the complexity of its clinical presentation," says Cesare Orlandi, executive R&D director of Medco.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.